The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
$650m buys the group rights to RemeGen’s RC148.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
After Aktis's $318m flotation Eikon is a bigger proposition.
Readout of the Pivot-006 trial is brought forward by nearly a year.
